FDA Label Expansion And SYFOVRE Will Unlock Future Value
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
02 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$37.74
25.9% undervalued intrinsic discount15 Aug
US$27.97
1Y
-30.3%7D
0.8%